Search clinical trials for: NYX-2925

Total 502 results

Mie University
Fiverings Co., Ltd.; Shionogi; Takara Bio Inc.; Statcom Co. Ltd.

Unknown

Investigator Initiated Phase 1 Study of TBI-1301

Solid Tumors

Japan
AstraZeneca

Completed

A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy (CHASE 2)

Asthma

United States, South Africa, Hungary, Bulgaria, Czech Republic, Poland
Jonsson Comprehensive Cancer Center

Active, not recruiting

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Malignant Neoplasm

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Unspecified Adult Solid Tumor, Protocol Specific

United States
Duke University
National Institute of Mental Health (NIMH)

Completed

Treatment of Obsessive Compulsive Disorder in Children

Obsessive-Compulsive Disorder

United States
NeuroRx, Inc.
Target Health Inc.

Completed

NRX101 Glx Biomarker Validation Study (NRX-GLX)

Suicidal Ideation | Bipolar Depression

United States
NicOx Research Institute S.r.l.

Completed

Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)

Intermittent Claudication

Italy
Braeburn Pharmaceuticals

Completed

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

Opioid Use Disorders

United States
Medical University of Vienna

Completed

Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)

Vulvovaginal Candidiasis

Austria
London School of Hygiene and Tropical Medicine
University of Copenhagen; National Institute for Medical Research, Tanzania; Kilimanjaro...

Completed

Kilimanjaro IPTi Drug Options Trial

Malaria

Tanzania
Baylor Research Institute

Terminated

Nitrous Oxide for Analgesia During Office Urethral Bulking

Pain | Stress Incontinence, Female

United States
Tianjin Medical University Cancer Institute and...

Unknown

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

Chemotherapy Effect | Susceptibility, Genetic

China
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Sarcoma | Glioblastoma | Recurrent Ovarian Carcinoma | Recurrent Uterine Corpus Carcinoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Metastatic Renal Cell Cancer | Recurrent Lung Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Sanofi Pasteur, a Sanofi Company

Completed

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage... and other conditions

United States
Gilead Sciences

Terminated

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

United States
AstraZeneca

Active, not recruiting

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD)

Non-Small Cell Lung Cancer

Denmark, Italy, Spain, United States, Korea, Republic of, Japan, Netherlands, Norway, Sweden
M.D. Anderson Cancer Center

Recruiting

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Myxoid/Round Cell Liposarcoma | Synovial Sarcoma

United States
Cairo University

Completed

Caudal Epidural Catheterization in Pediatric Renal Transplant: Effect on Hemodynamics and Pain After Surgery

Renal Failure

Egypt
Cairo University

Not yet recruiting

Erector Spinae Plane Block Versus Quadratus Lumborum Block for Open Renal Surgeries in Children

Postoperative Pain, Acute
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Dendritic Cell Vaccination During Lymphoid Reconstruction

Intraocular Melanoma | Melanoma (Skin)

United States
Yonsei University

Recruiting

Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial

Ischemic Heart Disease

Korea, Republic of
M.D. Anderson Cancer Center

Recruiting

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Myeloma

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Eunice Kennedy Shriver... and other collaborators

Completed

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 (NYM)

Childhood Solid Neoplasm | Metastatic Neoplasm | Adult Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Melanoma | Breast Cancer | Non-Small Cell Lung Cancer | Meningioma | Hepatocellular Cancer

United States
Fiona Thistlethwaite
Karolinska University Hospital; University College London Hospitals; Erasmus... and other collaborators

Terminated

NY-ESO-1 T Cells in OG Cancer (ATTACK-OG)

Oesophageal Cancer

United Kingdom
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)

Terminated

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

Metastatic Cancer | Metastatic Melanoma

United States
Mclean Hospital
Stanley Medical Research Institute

Completed

Effects of Pentazocine Versus Lorazepam on Manic Symptoms

Schizoaffective Disorder | Bipolar Disorder | Mania | Manic Disorder | Manic State

United States
Kirstine Nyvold Bojsen-Moeller
University of Copenhagen

Unknown

The Effect of Different Macronutrients on Gastrointestinal Hormone Secretion After Gastric Bypass Operation

Overweight | Bariatric Surgery (Gastric Bypass)

Denmark
UNC Lineberger Comprehensive Cancer Center

Recruiting

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

Breast Cancer

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants

Healthy

United States
S1 Biopharma, Inc.

Completed

Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety (PURPLE)

Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined) | Sexual Interest/Arousal Disorder (DSM-5 Defined)

United States
National Institute on Drug Abuse (NIDA)

Not yet recruiting

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Methamphetamine-dependence | Methamphetamine Abuse
M.D. Anderson Cancer Center

Completed

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Recurrent Synovial Sarcoma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present | Recurrent Myxoid Liposarcoma

United States
University of Southern California
National Cancer Institute (NCI)

Not yet recruiting

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
Washington University School of Medicine
Celgene

Completed

Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer

Head and Neck Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Instituto Nacional de Cardiologia Ignacio Chavez

Terminated

Drug-eluting Balloon Versus Drug-eluting Stent for High Bleeding Risk Angioplasty (DEBORA)

Coronary Artery Disease (CAD) | Percutaneous Coronary Intervention (PCI) | High Bleeding Risk

Mexico
Roswell Park Cancer Institute
National Cancer Institute (NCI); Incyte Corporation; Celldex Therapeutics

Completed

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
NeuroRx, Inc.
Massachusetts General Hospital; Target Health Inc.

Completed

Sequential Therapy for the Treatment of Severe Bipolar Depression. (STABIL-B)

Suicidal Ideation | Suicide, Attempted | Bipolar Depression | Suicidal Ideas

United States
Janssen-Cilag International NV

Withdrawn

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Depressive Disorder, Treatment-Resistant
Roswell Park Cancer Institute

Completed

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Alkylating Agent-Related Acute Myeloid Leukemia | Refractory Anemia With Excess Blasts in Transformation

United States
National Cancer Institute (NCI)

Completed

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Ocular Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Cutaneous Melanoma | Mucosal Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage... and other conditions

United States
Roswell Park Cancer Institute
Eisai Inc.

Completed

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada
Hospital Universitari de Bellvitge

Terminated

Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression

Depression

Spain
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma

United States
Roswell Park Cancer Institute
Celldex Therapeutics

Completed

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Refractory Anemia | Blasts 30 Percent or Less of Bone Marrow Nucleated Cells

United States
Roswell Park Cancer Institute

Active, not recruiting

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Refractory Ovarian... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States

Search clinical trials for: NYX-2925

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations